Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Glaucoma, Open-Angle

In brief

A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.

Key facts

Study ID

NCT00693485

Run by

Allergan

People needed

70

Starts

2008-09-01

Expected to finish

2011-08-01

Last updated by the study team

2013-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary open-angle glaucoma in one eye
• Visual acuity 20/80 or better
• Intraocular pressure in the study eye ≤ 24 mm Hg
• Glaucomatous visual field loss - 7 dB to - 25 dB

You may not qualify if…

• Known allergy to brimonidine tartrate
• Uncontrolled systemic disease or infection of the eye
• Recent eye surgery or injections in the eye
• Female patients who are pregnant, nursing or planning a pregnancy

Where it is running

• Study site — Artesia, California, United States
• Study site — Tel Aviv, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.